We recently published a list of Thursday's 10 Worst-Performing Stocks. In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday's ...
As of Tuesday, August 25, Akebia Therapeutics, Inc.’s AKBA share price has surged by 5.01%, which has investors questioning ...
We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list. TheFly reported ...
Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient ...
) has been revised to $5.51 / share. This is a decrease of 27.03% from the prior estimate of $7.55 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
Akebia Therapeutics develops and markets therapies for people living with chronic kidney disease. Its key commercial products are Vafseo, an oral medicine that treats anemia in adults undergoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results